Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacogenomic Progress Hinges On Strong Pharma Backing – Consultant

This article was originally published in The Gray Sheet

Executive Summary

Reference labs developing less costly "homebrew" tests could supplant diagnostic firms as the vehicle for commercializing pharmacogenomic tests, consultant Richard Barker told attendees at the IBC Dx/Rx Summit March 9 in Reston, Va

You may also be interested in...



Genomic Patent Exclusivity Tackled By NIH “Best Practices” Draft Guidance

NIH is floating a three-page draft guidance on best practices for the licensing of genomic inventions

Genomic Patent Exclusivity Tackled By NIH “Best Practices” Draft Guidance

NIH is floating a three-page draft guidance on best practices for the licensing of genomic inventions

Drug/Diagnostic Partnerships Fueled By Promise Of Reduced Trial Costs

Diagnostic manufacturers should be careful to keep their alliances with drug companies open enough to accommodate pharmacogenomic advances, panelists agreed at Thomas Weisel Partners' Healthcare Tailwinds 2002 meeting in Boston April 29

Related Content

UsernamePublicRestriction

Register

MT019917

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel